Anthera Pharmaceuticals Inc (ANTH)
Anthera Pharmaceuticals, Inc. is a biotechnology company whose common stock trades on OTC Markets under the symbol ANTH. The company focuses on developing and commercializing medicines aimed at unmet medical needs. Its pipeline includes Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy being studied in Phase III for exocrine pancreatic insufficiency, and Blisibimod, a Phase II candidate being evaluated for B-cell mediated autoimmune diseases, including IgA nephropathy. Anthera also has license agreements with Amgen and Eli Lilly. Founded in 2004, the company is based in Houston, Texas.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-ANTH
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
0.026 K
|